Replies to post #3094 on Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

…would MNTA be compensated for agreeing to hold off with the introduction of mC into the market place?

Receiving a direct payment for delaying a generic launch is out of the question. Rather, the “compensation” to NVS/MNTA in such a settlement would be in having the patent-infringement suit against them dropped.